Author

Francesca Santacroce

Institutions: Novartis (Switzerland), Novartis Institutes for BioMedical Research

Observed institutions: Novartis (Switzerland), Novartis Institutes for BioMedical Research

OpenAlex ID: A5111609024

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

2015 · Hui Gao, Joshua M Korn, et al. · Nature Medicine · 1,387

Abstract 1224: Insights into the mechanism of action of NVP-HDM201, a differentiated and versatile Next-Generation small-molecule inhibitor of Mdm2, under evaluation in phase I clinical trials

2016 · Stéphane Ferretti, Ramona Rebmann, et al. · Cancer Research · 10

Abstract 4638: NVP-CGM097: a novel p53-Mdm2 inhibitor exhibiting potent antitumor activity in mouse models of human cancer

2014 · Stéphane Ferretti, Marjorie Berger, et al. · Cancer Research · 3

Works count: 3

Citation count: 1,400

H-index: 3

I10-index: 2